Alexza will update investors on its financial guidance during next week's first-quarter earnings call

Addex Therapeutics SA, of Geneva, disclosed positive preclinical data for its GABAB receptor-positive allosteric modulator in a rodent model of chronic alcohol dependence. The Addex alcoholism candidate, ADX71441, demonstrated robust and dose-dependent suppression of alcohol intake in animals lasting 24 hours. ADX71441 is an oral small molecule, with potential for once-daily dosing. In other news, Addex said dipraglurant demonstrated dose-dependent mGlu5 receptor occupancy in a nonhuman primate

were down nearly 10 percent Friday following Thursday's after-market release of first-quarter earnings, which included news that the San Diego-based biotech is pulling its European marketing application for obesity drug Belviq (lorcaserin), though the bigger disappointment may be the ongoing delay in Belviq's U.S...Gilead's Pipeline Overshadows Earnings Miss In its first-quarter earnings call, Gilead Sciences Inc

Zealand Pharma A/S, of Copenhagen, Denmark, said licensing partner Sanofi SA, of Paris, provided an update in its first-quarter earnings on the status of the Lantus (insulin glargine)/Lyxumia (lixisenatide) single combination development program

In a research note following the company's 2012 and fourth-quarter earnings call in March, Cowen and Co

While the reductions will produce cost savings in 2013, the company isn't expecting a significant adjustment to the current operating budget due to restructuring charges of about $1.9 million to be incurred this year, according to Geron's first quarter earnings report

Amgen Inc.'s first quarter earnings fell short of Wall Street estimates, with the Thousand Oaks, Calif.-based company posting $4.24 billion in revenues, shy of the $4.38 billion expected by consensus

Aeterna Zentaris has not yet reported fourth-quarter earnings

Achillion also reported fourth-quarter earnings, with a net loss of $11 million and guidance that estimates spending on research and development at $50 million in 2013, with a burn spaced evenly over the quarters, at about $12 million per three-month period

Higher-than-expected product sales pushed Gilead Sciences Inc.'s fourth-quarter earnings beyond the Street's expectations, according to the company's earnings report released Monday

Biogen Idec Inc.'s fourth-quarter earnings missed estimates, but Wall Street barely noticed as revenue topped expectations, driven largely by steady growth in multiple sclerosis (MS) drugs Avonex (interferon beta-1a) and Tysabri (natalizumab), with investors already looking ahead to the much-anticipated launch of oral MS drug BG-12

And on the eve of reporting its third-quarter earnings, Eli Lilly and Co

And on the eve of reporting its third-quarter earnings, Eli Lilly and Co

Two weeks ago, following Transcept's third-quarter earnings call, Cowen and Co

BioCryst reported a net loss of $9.7 million, or 19 cents per share, in its third-quarter earnings...Catalyst has not yet reported its third-quarter earnings

reported its third-quarter earnings, handing in a net loss of $154.9 million, or $1.04 per share...J.P. Morgan's Cory Kasimov called Dendreon's third-quarter earnings results "again disappointing," but noted some underlying favorable trends, including traction gained in the urology setting, "which we believe is critical for future sales growth

Prospects for the compound, partnered with Biogen Idec Inc., of Weston, Mass., generated instant buzz among analysts awaiting Biogen Idec's third-quarter earnings Thursday

In its third-quarter earnings, Sanofi referred to the rare disease and MS franchises as the "new Genzyme

Biogen Idec Inc., of Weston, Mass., reported in its third-quarter earnings call that it will not proceed with a planned Phase IIa rheumatoid arthritis (RA) study of its Syk inhibitor partnered with Portola Pharmaceuticals Inc., of South San Francisco